The Trump administration finalized a rule barring Medicaid and CHIP from covering puberty blockers, cross-sex hormones, and surgeries for minors, a move HHS says follows a sweeping review that found serious risks and no reliable proof of benefit.
HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz announced the ban on Tuesday, making the federal government's position explicit: taxpayer dollars through Medicaid and the Children's Health Insurance Program will no longer pay for gender-transition drugs or surgeries performed on children. The final rule, issued by the Centers for Medicare and Medicaid Services, takes effect October 13, 2026.
CMS described the rule as "consistent with its commitment to protect children from experimental and life-altering" procedures "that carry serious long-term health risks and lack sufficiently reliable evidence of clinical benefit." The agency said the covered procedures "can result in irreversible damage, including infertility, impaired sexual function, diminished bone density, altered brain development, and other lasting physiological effects."
The rule does not touch coverage for mental health services. And children currently receiving hormone therapy funded by Medicaid or CHIP will get a tapering-off period of up to six months, an acknowledgment that abruptly stopping certain hormonal treatments carries its own medical risks.
Kennedy framed the decision in blunt terms. Breitbart News reported his statement:
"Today, we are ending federal taxpayer funding for sex-rejecting procedures on children. These interventions carry serious risks and can cause irreversible harm. The federal government will no longer use Medicaid and CHIP dollars to fund procedures that fail to meet the evidentiary standard our children deserve."
Oz echoed that line, tying the decision directly to the evidence base, or, more precisely, the lack of one:
"Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits. By cutting off federal funds for these sex-rejecting procedures, we're following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm so they can truly flourish."
HHS said its decision followed a review of national and international research. CMS pointed to the United Kingdom's Cass Report, a landmark 2024 review commissioned by Britain's National Health Service, as part of the international evidence landscape that informed the rule. Sweden has also moved to restrict similar treatments for minors.
That international trend matters. Countries with single-payer health systems and no American culture-war incentives examined the same medical literature and reached the same conclusion: the evidence does not support routine use of puberty blockers and cross-sex hormones in children. When Britain, Sweden, and now the U.S. federal government all land in the same place, the burden shifts to defenders of these procedures to explain what evidence they are relying on.
President Trump praised the move in a post on Truth Social, saying he had directed Oz to make the announcement:
"Today, at my direction, Dr. Mehmet Oz announced that Medicaid will NO LONGER fund gender transition surgeries and hormones for minors. We are not going to pay for our innocent children to undergo these barbaric surgeries and practices, which result in unthinkable and irreversible harm to their young bodies."
Trump also claimed credit for a wider shift already underway in the medical establishment. "Thanks to our strong position and pressure on this issue over the past year and a half, dozens of U.S. hospitals have already ended this so-called 'gender-affirming care,' and we expect many more to follow," he wrote.
That claim, "dozens of U.S. hospitals", is Trump's characterization, and the Breitbart report does not independently verify the number. But the direction of the trend is not in serious dispute. CMS itself referenced recent policy shifts by the Society of Plastic Surgeons as further evidence that the medical profession is pulling back from these interventions for minors. And a related report noted that Connecticut Children's Medical Center reached an agreement with the Department of Justice to end sex-change drugs for minors, a sign that federal enforcement pressure is producing results facility by facility.
The scope of the ban is specific. It covers three categories of intervention when performed on minors: puberty blockers, cross-sex hormones, and surgical procedures related to gender transition. All three lose Medicaid and CHIP funding once the rule takes effect in October.
Mental health services remain covered. That distinction is worth noting because critics of restrictions like this one often argue that cutting off medical interventions leaves children without any support. The rule draws a clear line: therapy and counseling stay funded; drugs and surgeries that carry permanent physical consequences do not.
The six-month tapering window for children already on hormone therapy reflects a clinical reality. Stopping hormonal treatments suddenly can produce adverse effects. The rule accounts for that by giving doctors time to manage the transition off these drugs safely, a detail that undercuts any argument that the administration acted without regard for children currently in treatment.
Trump did not pretend the announcement exists in a political vacuum. His Truth Social post ended with a direct appeal to voters ahead of the midterm elections in November. "While the Dumocrat Party wants your kids to be able to chop off their reproductive organs before they are old enough to vote, President Donald J. Trump (ME!) and the Republican Party say that is ABSURD, and we will protect America's children," he wrote. "Please remember this when you are casting your vote in the Midterm Elections in November."
The political framing is Trump's own. But the policy question underneath it is straightforward: Should federal tax dollars fund experimental procedures on children when the government's own research review found serious safety concerns, significant evidence gaps, and no reliable proof of clinical benefit?
CMS answered that question on Tuesday. The agency concluded that these procedures do not meet the evidentiary standard that federal health programs require. That is not a culture-war talking point. It is a regulatory determination grounded in the same kind of evidence review that governs every other federally funded medical intervention.
Several open questions remain. How many children currently receive Medicaid- or CHIP-funded hormone therapy and will need to taper off? What specific studies did HHS weigh in its research review beyond the Cass Report? And will legal challenges from advocacy groups or blue-state attorneys general attempt to block the rule before its October effective date? The administration has not addressed those questions publicly.
For years, a small but influential corner of the medical establishment pushed gender-transition procedures on minors while dismissing concerns about long-term harm as bigotry. Country after country has since reversed course. Now the federal government has, too. The children who will never be put on puberty blockers at taxpayer expense are the ones who benefit most, and they will never know it.
